Overview
This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.
Description
This study is an observational study to evaluate the effectiveness and safety of secukinumab in patients with ankylosing spondylitis who are naive to TNFi/JAKi/IL-17i in Korea. Subjects will be recruited from 10 institutions in Korea. The enrollment period is 8 months from the initiation at the first institution and the follow-up periods are 28 weeks(±4 weeks). Data will be gathered at initial visit, 16 weeks(±4 weeks), and 28 weeks(±4 weeks).
Secukinumab is prescribed within the scope of labeling approved in Korea.
Eligibility
Inclusion Criteria:
- Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria
- Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of ≥ 4
- Subjects who have never used TNFi, JAKi, or IL-17i drugs before
- Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety
- Subjects who have a time of less than 5 years since AS diagnosis
- Subjects who are above the age of 18 years and below 40years old
- Subjects who give informed consent form to participate in the study
Exclusion Criteria:
- Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks)
- Subjects who have congenital/traumatic spinal deformities
- Subjects currently enrolled in other clinical studies
- Subjects who have any contraindications to secukinumab treatment